Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00356018 · ClinicalTrials.gov registry record
Compliance With Once-Daily Divalproex Extended-Release Tablets (Depakote-ER) Versus Multiple-Daily Dose Valproic Acid Capsules (Depakene) in Epilepsy:
A clinical trial, sponsored by Orlando Health.
- Completed
- Registry status
- 5
- Enrollment target
NCT00356018 is a clinical trial that has completed, run by Orlando Health. The registered enrollment target is 5 participants.
The verdict
NCT00356018 has completed, sponsored by Orlando Health.
- COMPLETED
- Registry status
- 5 participants
- Enrollment target
Study Summary
To determine, in a randomized, parallel open-label fashion, compliance rates between once-daily extended-release divalproex sodium tablets (Depakote-ER®, Abbott Labs) versus multiple-daily dose valproic acid capsules (Depakene®, Abbott Labs) in an epilepsy population.
Interventions
- BEHAVIORAL Compliance
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2006-07 |
| Est. Completion | 2007-05 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00356018
The ClinicalTrials.gov registry entry for NCT00356018 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Orlando Health, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Compliance is the first listed.
NCT00356018 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00356018 about?
NCT00356018 is a clinical study titled "Compliance With Once-Daily Divalproex Extended-Release Tablets (Depakote-ER) Versus Multiple-Daily Dose Valproic Acid Capsules (Depakene) in Epilepsy:". To determine, in a randomized, parallel open-label fashion, compliance rates between once-daily extended-release divalproex sodium tablets (Depakote-ER®, Abbott Labs) versus multiple-daily dose valproic acid capsules (Depakene®, Abbott Labs) in an epilepsy population.
What is the current status of trial NCT00356018?
This trial is currently completed. The enrollment target is 5 participants. The study started on 2006-07. Estimated completion is 2007-05.
What interventions are being tested in trial NCT00356018?
The interventions under investigation include: Compliance (BEHAVIORAL).
Who is sponsoring clinical trial NCT00356018?
This trial is sponsored by Orlando Health, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.